Correlation of thyroid stimulating hormone receptor mRNA expression levels in peripheral blood with undesirable clinicopathological features in papillary thyroid carcinoma patients
Metrics: PDF 976 views | HTML 1816 views | ?
Riming Liu1,*, Shaolong Hao2,*, Hua Zhang3, Jihong Ma2, Xincheng Liu2, Jie Xu2, Xin Liu4, Jinyao Ning2, Yan Sun3, Lixin Jiang2, Guojun Li5,6, Xicheng Song3 and Haitao Zheng2
1Department of Laboratory of Molecular Biology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong Province, China
2Department of Thyroid Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong Province, China
3Department of Otolaryngology-Head and Neck Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong Province, China
4Department of Central Laboratory, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong Province, China
5Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
6Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
*These authors contributed equally to this work and are considered co-first authors
Xicheng Song, email: email@example.com
Haitao Zheng, email: firstname.lastname@example.org
Keywords: papillary thyroid carcinoma, peripheral blood, TSHR mRNA, noninvasive detection
Received: November 30, 2016 Accepted: May 14, 2017 Published: May 26, 2017
To determine the extent to which thyroid stimulating hormone receptor (TSHR) mRNA in peripheral blood (PB) has diagnostic value for papillary thyroid carcinoma (PTC). We obtained pre- and postoperative PB samples from 104 thyroid disease patients and collected 11 healthy volunteers’ PB samples twice apiece at different times. We used reverse transcription polymerase chain reaction (RT-PCR) to quantify TSHR mRNA expression levels in the samples. T-test and chi-square test were used to compare quantitative data and rates. The mean preoperative PB TSHR mRNA expression level of the PTC patients was significantly higher than that of the healthy volunteers. However, on the postoperative day 1, PB TSHR mRNA level of PTC patients significantly decreased but not for healthy controls. Preoperative PB TSHR mRNA expression levels were significantly associated with patient age, capsular invasion status, lymph node metastasis status, and BRAFV600E mutation status (P < 0.05) but not gender, tumor size, number of cancer foci, or Hashimoto thyroiditis status. Preoperative assessment of the PB TSHR mRNA expression level combined with ultrasonography of the thyroid had better accuracy in the diagnosis of PTC than either method alone did. Moreover, TSHR mRNA expression significantly affected recurrence of PTC patients. Our findings suggest that PB TSHR mRNA expression level is a promising novel biomarker for the early detection, diagnosis, and treatment of PTC. It may serve as a noninvasive means of PTC detection and a prognostic biomarker of residual tumor and help guide further treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.